MarginsXMarginsX
Home › Markets › Health Care › DNLI

Denali Therapeutics Inc. (DNLI)

DNLI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$18.08
-3.52% on the day
Market cap
$2.9B
Mid cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$512.5M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/0001714899-26-000021-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDNLI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2017
SEC CIK0001714899
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$512.5M
Operating income-$555.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$205.3M
Total assets$1.1B
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
2.8 months
$102.9M cash at September 30, 2026
Share count, 1 year
+9.3%
2025-10-31 to 2026-10-28 · +16.0% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$1.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$102.9M cash; operating cash flow -$111.0M a quarter.Report 2026-09-30
Shares outstanding160,290,546 (2026-10-28); 146,661,833 a year earlier; 138,196,848 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-12-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$17.8M$70.1M-$117.4M$102.9MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q2 2026
2026-06-30
$3.6M-$127.6M-$97.0M$201.5MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2026
2026-03-31
Not filed-$128.4M-$131.2M$387.6MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q4 2025
2025-12-31
$0-$128.5M-$98.5M$205.3MNo debt tags$010-K 2026-02-26
Q3 2025
2025-09-30
$0-$126.9M-$107.3M$91.0MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q2 2025
2025-06-30
$0-$124.1M-$75.3M$141.2MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2025
2025-03-31
Not filed-$133.0M-$131.5M$56.9MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q4 2024
2024-12-31
$0-$114.8M-$83.7M$175.0MNo debt tags$010-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-10
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxy
DEFA14A ADDITIONAL MATERIALS
DEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 790 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.6%
1 month+1.8%
3 months-24.5%
Year to date+13.5%
1 year+9.3%
From 52-week high-31.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
VCELVericel Corporation$57.48+0.91%$2.9B
ADMAADMA Biologics Inc$13.47-1.54%$3.0B
IOVAIovance Biotherapeutics Inc.$7.55-2.71%$3.5B
RLAYRelay Therapeutics Inc.$17.27-4.53%$3.8B
BEAMBeam Therapeutics Inc.$20.94-8.28%$2.2B
TARSTarsus Pharmaceuticals Inc.$78.68-1.99%$3.9B
CRSPCRISPR Therapeutics AG Common Shares$40.37-4.43%$3.9B
REPLReplimune Group Inc.$21.41-2.19%$2.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier